Clinical trials: Convulsion, Non-Epileptic
Epilepsy
Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy
The aim of the study is to prove the feasibility and safety of transcutaneous, electrical stimulation of the vagus nerve in patients with difficult-to-treat forms of epilepsy.
- Trial name
- NCT01178437
- Testing
- T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- cerbomed GmbH
Neuralgia, Epilepsy
Clinical Study With Lyrica In Patients Suffering From Epilepsy
Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.
- Trial name
- NCT00922987
- Testing
- Lyrica (pregabalin)
- Where
- 61 sites in Slovakia
- Volunteers
- 286 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Status Epilepticus, Convulsive Status EPILEPTICUS
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.
- Conditions
- Status Epilepticus, Convulsive Status EPILEPTICUS, Non Convulsive Status Epilepticus, Epilepsy
- Trial name
- NCT03350035
- Testing
- IV Ganaxolone active
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy
Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)
This is a multicenter, non-interventional, prospective study. The observation period comprises at least 6 months, from the initiation of ESL add-on therapy in adult patients with partial-onset epilepsy not sufficiently controlled…
- Trial name
- NCT01532726
- Testing
- ESL
- Where
- Portugal
- Volunteers
- 56 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00175825
- Testing
- Brivaracetam
- Where
- 42 sites in United States, Brazil and 2 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Epilepsy, Tonic-Clonic
EpiWatch: Evaluation of a Non-EEG Physiological Signal Based Seizure Monitoring System
To demonstrate the safety and effectiveness of the EpiWatch device in identifying tonic-clonic (TC) seizures, notifying a third-party of TC seizure occurrence, and collecting non-EEG physiological data for subsequent review…
- Trial name
- NCT05059002
- Testing
- Physiological signal monitoring and seizure detection
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- EpiWatch, Inc.
KCNT1-Related Epilepsy
A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy
The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head growth, symptom severity, neurocognitive and social functions, adaptive…
- Trial name
- K1Te (NCT04924153)
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Epilepsy
GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin
- Trial name
- NCT00567424
- Testing
- GW273225
- Where
- 30 sites in United States
- Sponsor
- GlaxoSmithKline
Epilepsy
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
- Trial name
- NCT01091662
- Testing
- Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
- Where
- 62 sites in United States, Bulgaria and 3 more
- Volunteers
- 172 people
- Sponsor
- Sumitomo Pharma America, Inc.